Severe Acute Respiratory Syndrome Clinical Trial
Official title:
Contamination During Removal of Two Different Personal Protective Systems When Working Under Conditions Requiring Enhanced Respiratory and Contact Precautions
Highly communicable and virulent diseases, the ongoing threat of emerging infectious
diseases, and the prospect of bio-terrorism have become part of the new reality for health
care workers. SARS transmission has occurred despite the use of droplet, contact, and
airborne precautions. Potential explanations for some of the episodes of
“through-precautions” transmission include the possibility of contamination during removal
of protective clothing.
The recommended protective systems (PPS) for aerosol generating procedures set out by the US
Center for Disease Control and Prevention (CDC) and the Ontario Ministry of Health and Long
Term Care (MOHLTC) differ.
The failure of a PPS may be associated with significant consequences in terms of the
morbidity and mortality of front-line health care workers. The purpose of this study is to
determine if a difference exists between the rate of self-contamination due to deficiencies
in contact precautions for individuals wearing either the CDC or MOHLTC recommended PPS.
Study participants will don one of the two recommended PPS, be “contaminated” with an
indicator that becomes visible under ultraviolet light, and then assessed for contamination
of clothing layers and skin after removal of the PPS. They will then repeat the procedure
using the other PPS.
Background: Highly communicable and virulent diseases such as severe acute respiratory
syndrome (SARS) and “avian influenza”, the ongoing threat of other emerging infectious
diseases, and the prospect of bio-terrorism have become part of the new reality for health
care workers (1). Recent experience with SARS has demonstrated that front-line health care
professionals who perform or assist with aerosol generating procedures are at particularly
increased risk of infection.
At present, no data exists addressing the question of self-contamination during the removal
of personal protective systems used in a health care setting. The latest suggested donning
and removal procedures have not been validated with respect to the issue of
selfcontamination due to deficiencies in contact precautions.
The failure of a personal protective system or the donning and removal procedures for a
personal protective system may be associated with significant consequences in terms of the
morbidity and mortality of front-line health care workers. It is imperative that the rate of
self-contamination for these two personal protective systems be assessed.
The purpose of this study is to determine if a difference exists between the rate of
self-contamination due to deficiencies in contact precautions for individuals wearing either
Personal Protective Equipment (PPE) or the Powered Air Purifying Respirator (PAPR).
This will be a prospective, randomized, controlled, crossover study.
Institutional Ethics Committee approval will be obtained for this study. Fifty participants
will be required for the study. Participants will be recruited from the Department of
Anesthesiology attending and resident staff, other physician groups requiring PAPR training,
and the Department of Respiratory Therapy. Recruitment will occur in conjunction with annual
training in the use of the PAPR. Individuals will be informed of the purpose and procedure
of the study and written consent will be obtained. Individuals will be excluded if they
refuse to provide written consent to participate in the study.
Participants will wear operating room scrub attire as their base clothing layer.
They will be randomized to don either the PAPR or PPE. They will then repeat the process
using the other personal protective system immediately after the study protocol has been
completed using the first personal protective system.
PPE will consist of an N95 respirator, goggles, face shield, bouffant hair cover, fluid
resistant surgical gown, and fitted sterile gloves. Although the CDC has omitted a head
covering as part of their PPE, the MOHLTC directives stipulate that a head covering must be
worn when performing high-risk procedures in patients that require enhanced respiratory and
contact precautions. A head covering (bouffant hair cover) will therefore form part of the
PPE used in this study. The CDC recommendations state that goggles can be worn for eye
protection. A face shield can be used in addition to the goggles but this is optional. The
MOHLTC directives state that goggles and a face shield must be worn during high-risk
procedures in patients that require enhanced respiratory and contact precautions. Goggles
and a face shield will therefore form part of the PPE for this study. Therefore the donning
and removal instructions for the PPE that will be used for this study will differ in
sequence from those published by the CDC. The donning and removal procedures that will be
used for this study more closely follow the sequence recommended by the MOHLTC and are
indeed an enhanced version of those directives.
PAPR will consist of a body suit and shoe covers, PAPR hood and power unit, N95 respirator,
goggles, face shield, bouffant hair cover, fluid resistant surgical gown, and fitted sterile
gloves. The MOHLTC has stipulated the use of donning/removal coaches for the PAPR. Neither
the CDC, the MOHLTC, nor our institution have stipulated the use of donning/removal coaches
for the PPE. The intent of this study is to examine the protective systems. The donning and
removal procedures that form part of the protective systems may either contribute to or
minimize self-contamination rates and must be assessed under the actual conditions of use.
In order to best simulate the actual conditions that health care workers will be subjected
to and to best evaluate donning and removal procedures and practices we have also decided
not to employ a donning/removal coach for the PPE. Accordingly, during donning and removal
of PPE participants will be given standardized written instructions outlining the donning
and removal procedure but will not be coached.
Participants will be given standardized written instructions and coached by a respiratory
therapist during donning and removal of the PAPR. The standardized written instructions for
donning and removal of both the PPE and PAPR are attached in Appendices A and B.
All participants will be timed and videotaped during the protective system donning
procedure. Timing will commence when the participants are instructed to begin reading 3
their written donning instructions for PPE or when the dressing coach says “begin” for the
PAPR. Timing will cease when the participants have completed donning the final item of the
protective system being tested. Videotaping will occur in order to record and assist in the
detection of any protective system donning procedure violations. A donning procedure
violation will be defined as having occurred if the participants perform a donning maneuver
out of sequence or touch a piece of protective equipment out of sequence. Participants will
be “contaminated” using a solution of fluorescein (1ml of a 25% solution diluted in 100cc
sterile water) in a standardized fashion. A Devilbiss atomizer (Model DV-15-RD, Sunrise
Medical Products, Carlsbad, California, USA) will be used to apply 5ml of fluorescein
solution to the their front face shield and torso. We have chosen these contamination sites
in order to simulate areas that would most likely be contaminated by the large respiratory
droplets aerosolized by a patient that is either coughing or reacting to intubation attempts
or any other high-risk respiratory procedure.
The atomizer nozzle will be held at a distance of 30cm from the participants’ face-shield
and will be applied from their shoulder level. The spray stream will be directed at the
participants’ nose and then aimed inferiorly towards the their umbilicus in an upwards and
downwards sweeping motion while keeping the atomizer oriented in the participants’
mid-saggital plane. Application will occur until the atomizer reservoir is empty. During
this application the participants’ eyes will be closed.
“Invisible” Detection Paste (Sirchie, 100 Hunter Place, Youngsville, NC) will be applied to
the palmar aspects of the participants’ hands and anterior and posterior forearm to the
elbow. Although the paste is labeled “invisible detection paste” it becomes visible when
viewed under ultraviolet (UV) light. 15ml of paste will be used. We have chosen to use
detection paste on the forearms and gloves of the study participants as these are the areas
most likely to come in contact with any patient requiring enhanced contact and respiratory
precautions. Participants will be videotaped, photographed with a digital camera, and
assessed with a UV lamp (Burton Medical Products Inc, 21100 Lassen Street, Chatsworth, CA.
91311 USA) following contamination to ensure that standardized contamination of their front
face shield, torso, forearm, and palmar aspect of the gloved hands has been achieved.
Participants will then follow the standardized written removal procedures for the protective
system that they are wearing. They will be timed and videotaped during the protective system
removal procedure. Timing will commence when the participants are instructed to begin
reading their written removal instructions for PPE or when the dressing coach says “begin”
for the PAPR. Timing will be paused during assessments with the UV lamp. Timing will cease
when the participants have completed removing the final item of the protective system being
tested. Videotaping will occur in order to record and assist in the detection of any
protective system removal procedure violations. A removal procedure violation will be
defined as having occurred if the participants perform a removal maneuver out of sequence,
touch a piece of protective equipment out 4 of sequence, or touch any part of their body
other than a piece of protective equipment prior to performing final hand disinfection.
Participants will be assessed with the UV lamp at specific intervals during the removal
procedure in order to detect any visible contamination. Participants in PPE will be assessed
with the UV lamp following removal of the outer PPE protective layer (outer fitted sterile
gloves, fluid resistant surgical gown, and faceshield).
Final assessment will occur after removal of the inner PPE protective layer (N95 mask,
goggles, bouffant hair cover, inner fitted sterile gloves). Participants in PAPR will be
assessed using the UV lamp after removal of the outer PAPR protective layer (PAPR hood and
power unit, outer fluid resistant surgical gown, outer boot covers, outer fitted sterile
gloves). They will then be assessed after removal of the middle PAPR protective layer (body
suit, middle sterile fitted gloves, boot covers).
Final assessment will occur after removal of the inner PAPR protective layer (N95 mask,
goggles, bouffant hair cover, inner sterile fitted gloves). An evaluator blinded to the
participants’ protective system will perform final assessment.
All areas of the participants’ base clothing layer and any exposed skin and hair will be
inspected after removal of the final protective layer. This will include the participants’
face. Contamination episodes will be counted and the contamination area will be calculated
in cm2.
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04542915 -
COVID-19-Related Health and Practices Among Dental Hygienists
|
||
| Completed |
NCT04515147 -
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
|
Phase 2 | |
| Recruiting |
NCT04480333 -
Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831
|
Phase 1 | |
| Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 | |
| Withdrawn |
NCT04838847 -
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
|
Phase 3 | |
| Not yet recruiting |
NCT04386070 -
Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
|
Phase 3 | |
| Withdrawn |
NCT00073086 -
Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS)
|
N/A | |
| Active, not recruiting |
NCT04527432 -
COVID-19 Health Professional Impact Study
|
N/A | |
| Completed |
NCT00215826 -
Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers
|
Phase 2 | |
| Completed |
NCT04366934 -
Study of the Pathogenesis of Olfactory Disorders in COVID-19
|
||
| Completed |
NCT04376684 -
Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
|
Phase 2 | |
| Completed |
NCT04402060 -
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT04395144 -
COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss
|
N/A | |
| Completed |
NCT04357730 -
Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection
|
Phase 2 | |
| Completed |
NCT04425213 -
Obesity and Mortality of Critically Ill Patients With COVID-19
|
||
| Completed |
NCT04425863 -
Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19
|
||
| Completed |
NCT06287554 -
Effect of Early Implementation of Prone Positioning
|
||
| Completed |
NCT04328129 -
Household Transmission Investigation Study for COVID-19 in Tropical Regions
|
N/A | |
| Completed |
NCT04602351 -
Communication in ICU During COVID-19
|
||
| Completed |
NCT03225807 -
Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure
|